Woodline Partners LP Raises Stake in Arvinas, Inc. (NASDAQ:ARVN)

Woodline Partners LP boosted its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 39.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 692,733 shares of the company's stock after buying an additional 194,996 shares during the period. Woodline Partners LP owned approximately 1.01% of Arvinas worth $13,280,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ARVN. KBC Group NV grew its stake in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas in the 4th quarter valued at approximately $171,000. Tema Etfs LLC acquired a new stake in shares of Arvinas in the 4th quarter valued at approximately $227,000. Teacher Retirement System of Texas boosted its stake in shares of Arvinas by 19.0% in the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after purchasing an additional 2,280 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Arvinas by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after purchasing an additional 1,367 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Price Performance

Shares of NASDAQ:ARVN traded up $0.04 during mid-day trading on Friday, hitting $6.51. The company had a trading volume of 1,244,283 shares, compared to its average volume of 1,338,700. The firm has a fifty day moving average price of $7.48 and a 200 day moving average price of $15.32. The company has a market capitalization of $475.17 million, a PE ratio of -2.35 and a beta of 2.21. Arvinas, Inc. has a one year low of $5.90 and a one year high of $36.20.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the company posted ($0.97) earnings per share. The company's revenue was up 646.2% on a year-over-year basis. Research analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ARVN. Jefferies Financial Group restated a "hold" rating and issued a $10.00 price target (down from $52.00) on shares of Arvinas in a research note on Friday, May 2nd. BTIG Research set a $16.00 price target on shares of Arvinas and gave the company a "buy" rating in a research note on Friday, May 2nd. UBS Group reduced their price target on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. Oppenheimer downgraded shares of Arvinas from an "outperform" rating to a "market perform" rating in a research note on Tuesday, March 11th. Finally, Citigroup reduced their price target on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating on the stock in a research note on Monday, May 5th. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $20.92.

Insider Activity at Arvinas

In related news, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the sale, the insider now owns 110,023 shares of the company's stock, valued at approximately $945,097.57. This trade represents a 7.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,230 shares of company stock valued at $769,402. 4.73% of the stock is owned by company insiders.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.